Get started
Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 ShGilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 ShGilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh

Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsSeasonalsBonds

Trade ideas

GILD - Leading to the top ======= Volume ======= - increasing ========== Price Action ========== - rounding bottom recently ================= Technical Indicators ================= - Ichimoku >>> price above cloud >>> Green kumo budding >>> Tenken + Chiku - above clouds and pointing up >>> Kijun - Above clouds and pointing up ========= Oscillators ========= - MACD bullish - DMI bullish - StochRSI, bullish, near regions of overbought ========= Conclusion ========= - short to long term breakout swing - price may reverse at current level, to enter spot or wait for pullback at entry 2. ========= Positions ========= Entry - $122 Entry 2 - $118 Stop - $110 Exit 1 - $128 Exit 2 - $133 Exit 3 - $138 Exit 4 - $143 Exit 5 - $150
NASDAQ:GILDLong
by Creedxx
Gilead’s Critical Battle at the Uptrend Line! Analysis: The daily chart of Gilead Sciences (GILD) shows that the stock, after a short-term correction, is once again approaching its main uptrend line (blue). The 50-day moving average (orange) around $114.50 acts as a key support level, and the current price is trading slightly above it. At this stage, the stock sits at a decisive point — it could either reclaim its bullish momentum by breaking above resistance or enter a deeper corrective phase if support fails. Short-term outlook (2–4 weeks): If the price manages to hold above $118, the next upside targets are in the $119.80–$124.80 range. This area represents the short-term bullish objective. A reasonable stop loss for this scenario is just below $114. Long-term outlook (2–3 months): If the stock breaks decisively above $125 and maintains that momentum, the next major targets would be in the $130–$134 range, which also aligns with the previous highs. However, if the blue uptrend line breaks down and a daily candle closes below $113, a bearish move toward the $106–$108 range becomes likely. In that bearish scenario, the stop loss should be placed above $113. Overall, GILD is at a decision point. As long as it trades above $114, the bullish outlook remains valid — but losing that support could shift the balance in favor of the bears.
NASDAQ:GILDShort
by isahebdadi
1
GILD at a Key Decision Zone!📊 Technical Analysis of GILD (NASDAQ) After a strong rally since the beginning of the year, the price is now testing a major ascending trendline support around $112 – $110. ✅ If the support holds and the price rebounds, we could see continuation towards the next resistance levels at $118 and $125. ❌ However, a breakdown below $110 with confirmation may trigger a deeper correction, opening the way towards $105 and potentially $98. 🔹 The reaction to this critical support zone will determine the next major move for GILD.
NASDAQ:GILDLong
by isahebdadi
1
GILD Ichimoku Breakout – Targeting 13% UpsideGilead Sciences (GILD) has broken above cloud resistance and the conversion line on the daily Ichimoku chart, setting up a clean breakout trade. Entry: $108.88 Target: $123.81 (+13.71%) Stop: $104.15 (-4.34%) Risk/Reward Ratio: 3.16 Volume & Momentum: Confirmed by CM_Ult_MacD and Williams %R near overbought (-19.91) Price has cleared the cloud with bullish structure and higher lows. Strong follow-through could push GILD toward the R1 pivot near $124.80.
NASDAQ:GILDLong
by yieldzilla888
GILD is a dangerous buy, but a buy nonetheless for me.There is a lot NOT to like about this trade. Yes, I see how far it has run. Yes, I see how fast it is falling. Yes, I see the gap from 96 to 102 that “must” be filled. Yes, the market overall has been unhelpful of late. I realize all of it and I wouldn’t necessarily recommend anyone follow me on this trade because of all of that. Here’s my “bull” case, such that it is with the way I trade. It's solidly in a long term uptrend. I know I’m jinxing myself with this, but GILD hasn’t had a trade with my system last longer than 5 days in almost a year. I did one last Friday that took 1 day to pay off, so going back so soon is REALLY tempting fate. But I am a slave to the data. The long term W/L record at this point is 988-0 for GILD. The average gain for those trades is +2.55% in an average of 13 trading days. The vast majority have closed in 2 days or less. Those numbers are a compelling argument for me. It is very possible, given the recent market action and its own price action, that this will be a longer than average trade in GILD. But it could also be like last Friday’s trade, too - one and done. There isn’t much else that is appealing to my algo right now - yesterday there was literally only one large cap stock that was a buy and it wasn’t in the top half of my rankings, so I didn’t trade it. Today this is one of fewer than 10, and the others are all lower tier stocks for me, historically. So here’s hoping I catch lightning in a bottle twice in one week with this stock. Entered my initial position at the close for 107.51. Per my usual strategy, I'll add to my position at the close on any day it still rates as a “buy” and I will use FPC (first profitable close) to exit any lot on the day it closes at any profit. As always - this is intended as "edutainment" and my perspective on what I am or would be doing, not a recommendation for you to buy or sell. Act accordingly and invest at your own risk. DYOR and only make investments that make good financial sense for you in your current situation.
NASDAQ:GILDLong
by redwingcoach
1
Gilead Sciences (GILD) Soars 4.93% on Strong Q4 Earnings ReportsGilead Sciences (NASDAQ: NASDAQ:GILD ) is making waves in the biotech sector after delivering a stellar fourth-quarter earnings report that not only crushed Wall Street expectations but also set the stage for a promising 2025. The stock surged 4.50% in premarket trading on Wednesday, signaling strong investor confidence in the company’s growth trajectory. Quarter and Optimistic Guidance Gilead’s Q4 earnings report was nothing short of impressive. The company posted adjusted earnings of $1.90 per share, a 10.5% year-over-year increase, and handily beat analysts’ estimates of $1.74. Revenue climbed 6% to $7.57 billion, surpassing the consensus forecast of $7.15 billion. HIV Franchise Shines Bright Gilead’s HIV portfolio remains its crown jewel. Biktarvy, the company’s flagship HIV treatment, generated $3.8 billion in sales, up 21% year-over-year and well ahead of the $3.47 billion forecast. Descovy, another HIV drug, also outperformed expectations, with sales rising 21% to $616 million. Combined, Gilead’s HIV product sales reached $5.45 billion, up 16% from the previous year. Looking ahead, Gilead is poised to expand its HIV franchise further with the anticipated mid-2025 launch of lenacapavir, a twice-yearly injectable for HIV prevention. The U.S. Food and Drug Administration (FDA) is expected to make a decision on the drug by mid-2024, and its approval could be a significant growth catalyst. Oncology and Liver Disease: Steady Growth Gilead’s oncology and liver disease segments also contributed to the strong quarter. Sales of its cell therapies for cancer treatment rose 5% to $488 million, beating expectations of $476 million. Trodelvy, a cancer drug, saw sales jump 19% to $355 million, surpassing the $324 million forecast. Liver disease treatments brought in $719 million, up 4% year-over-year. Veklury: The Only Blemish The only downside in Gilead’s report was Veklury, its COVID-19 treatment. Sales plummeted 53% to $337 million due to lower hospitalizations, particularly in the U.S. Upbeat 2025 Guidance Gilead’s bullish outlook for 2025 further fueled investor optimism. The company expects adjusted earnings of $7.70 to $8.10 per share on product sales of $28.2 billion to $28.6 billion. The midpoint of this guidance exceeds analysts’ estimates of $7.61 per share and $28.35 billion in revenue. Technical Analysis From a technical perspective, Gilead’s stock is showing strong bullish signals. As of Wednesday’s premarket trading, GILD is up 4.93%, poised to form a gap-up pattern upon market open. Key Levels to Watch - Resistance: A breakout above the 1-month high of $100 could serve as a critical catalyst for a sustained bullish run. This level represents a psychological barrier, and a decisive move above it could attract more buyers. - Support: In the event of a pullback, immediate support lies at the 65% Fibonacci retracement level, which aligns with the $92 mark. This level could act as a springboard for renewed upward momentum. RSI Indicates Room for Growth The Relative Strength Index (RSI) stands at 55, indicating that the stock is neither overbought nor oversold. This suggests there is ample room for further upside, especially if the broader market sentiment remains favorable. Conclusion Gilead Sciences (GILD) is firing on all cylinders, with a strong Q4 earnings beat, robust guidance for 2025, and a promising pipeline. The company’s leadership in the HIV market, coupled with its growing presence in oncology and liver disease, positions it well for long-term growth. From a technical standpoint, the stock is primed for a breakout, with key resistance and support levels offering clear markers for traders and investors.
NASDAQ:GILDLong
by DEXWireNews
Gilead Sciences (GILD): Will Support Hold or Will We See a Drop?We've neglected Gilead Sciences for a while, but it's time for an update. Unfortunately, our entry looking back wasn't ideal, as the stock has fallen below the 61.8% retracement level. It found support just below the 78.6% level, which marks the bottom of our range. This level was precisely touched, and we saw a relatively good movement upward from there. However, the outlook remains uncertain. We hope that the stock does not fall below this range bottom, as it would prompt us to consider cutting it. Our first take-profit target is at the range high around $86.5, but reaching this level will take time as Gilead Sciences is currently underperforming. Unlike most other stocks, Gilead Sciences operates in the research sector, not the tech sector. This means it follows a different cycle and is influenced by different capital flows. It tends to perform well when tech stocks do poorly. If tech stocks remain bullish, Gilead Science might continue to struggle. However, if there's a shift, Gilead Science could reverse and potentially reach up to $123, though this is quite far off. We are holding our position for now, hoping not to cut if the stock falls out of the range. If it does, we will take necessary action.
NASDAQ:GILDLong
by freeguy_by_wmc
Gilead Sciences (GILD): Pattern Still Intact—What’s the Plan?Let’s quickly review our open position in $GILD. We’ve managed to turn the whole chart around, and I hope everyone who bought in had the strength to sit it out. It was a close call with the stop loss, but now we’re up significantly, and we’ve moved our stop loss closer to $65.46. So far, we’re up 17%, and we don’t want to dictate when to take profits. If you’re in, do your own research and take profits whenever you feel comfortable—it's all up to you 👍. If you take a closer look, you’ll see that NASDAQ:GILD has been following a nice upward pattern: a surge, then three candles down, then another surge. I’m not sure how long this pattern will hold, but as long as we don’t retrace too much, we should be fine. I also like that we’re respecting all the key levels. The RSI is about to be overbought, so we might see another three candles down, but this time it could be a deeper pullback. We’ll see how it plays out, but we’re very pleased with this swing trade so far. Congratulations to everyone who’s been riding this wave 🍾.
NASDAQ:GILDLong
by freeguy_by_wmc
2
Gilead Sciences (GILD): First Take Profit in a High RangeGilead Sciences is now back trading at the high end of its range, and we’ve decided to take our first profit here. It’s crucial to respect range-bound trading, and there is a strong possibility of a pullback at this point. However, we don’t expect this pullback to reach the lower end of the range again but rather settle in the middle. If NASDAQ:GILD reclaims this range high, it could provide even more upside and new opportunities. We are also raising our stop loss to $65.80 to lock in gains. Gilead serves as our "natural hedge" against broader risk-on market conditions, and with a 40% bounce from the range low at the same time the S&P 500 is hitting new all-time highs, it’s clear that Gilead can benefit as well. We’re keeping a close eye on this stock, and if another opportunity arises, we’ll be ready to act.
NASDAQ:GILDLong
by freeguy_by_wmc